Weekly Analysts’ Ratings Updates for Opus Genetics (IRD)

by · The Markets Daily

Opus Genetics (NASDAQ: IRD) recently received a number of ratings updates from brokerages and research firms:

  • 9/10/2026 – Opus Genetics had its price target raised by Wedbush from $10.00 to $13.00. They now have an “outperform” rating on the stock.
  • 9/9/2026 – Opus Genetics had its price target raised by Chardan Capital from $13.00 to $16.00. They now have a “buy” rating on the stock.
  • 9/9/2026 – Opus Genetics had its price target raised by Oppenheimer Holdings, Inc. from $10.00 to $20.00. They now have an “outperform” rating on the stock.
  • 9/9/2026 – Opus Genetics had its “buy” rating reaffirmed by HC Wainwright. They now have a $8.00 price target on the stock.
  • 9/9/2026 – Opus Genetics had its “buy” rating reaffirmed by BTIG Research. They now have a $12.00 price target on the stock.
  • 9/9/2026 – Opus Genetics had its “buy” rating reaffirmed by Chardan Capital. They now have a $13.00 price target on the stock.
  • 8/16/2026 – Opus Genetics was upgraded by Wall Street Zen from “sell” to “hold”.
  • 8/11/2026 – Opus Genetics was upgraded by Zacks Research from “strong sell” to “hold”.
  • 8/8/2026 – Opus Genetics was upgraded by Wall Street Zen from “strong sell” to “sell”.
  • 8/7/2026 – Opus Genetics had its price target lowered by Royal Bank Of Canada from $10.00 to $9.00. They now have an “outperform” rating on the stock.
  • 7/29/2026 – Opus Genetics is now covered by TD Cowen. They set a “buy” rating on the stock.
  • 7/17/2026 – Opus Genetics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
  • 7/13/2026 – Opus Genetics was downgraded by Zacks Research from “hold” to “strong sell”.

Insiders Place Their Bets

In other Opus Genetics news, CFO Robert Gagnon sold 28,000 shares of the company’s stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $4.54, for a total value of $127,120.00. Following the completion of the transaction, the chief financial officer directly owned 556,375 shares of the company’s stock, valued at $2,525,942.50. This represents a 4.79% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO George Magrath sold 9,475 shares of Opus Genetics stock in a transaction dated Thursday, July 23rd. The stock was sold at an average price of $2.95, for a total value of $27,951.25. Following the sale, the chief executive officer directly owned 1,731,869 shares in the company, valued at approximately $5,109,013.55. The trade was a 0.54% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 57,331 shares of company stock worth $213,749 in the last quarter. 11.70% of the stock is currently owned by company insiders.

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.

Featured Stories